Results 31 to 40 of about 853 (171)
Antifungal resistance, combinations and pipeline: oh my!
Drugs in Context, 2023 Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically, Candida was responsible for approximately 15% of all nosocomial bloodstream infections.
Kayla R Stover +4 more
doaj +1 more source
The fungal expel of 5-fluorocytosine derived fluoropyrimidines mitigates its antifungal activity and generates a cytotoxic environment [PDF]
, 2022 Invasive aspergillosis remains one of the most devastating fungal diseases and is predominantly linked to infections caused by the opportunistic human mold pathogen Aspergillus fumigatus.
Alcazar-Fuoli, Laura +7 more
core +1 more source
Journal of Fungi, 2022 Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established
Nathan P. Wiederhold
doaj +1 more source
Journal of Fungi, 2023 The epidemiology of invasive fungal infections (IFIs) is currently changing, driven by aggressive immunosuppressive therapy, leading to an expanded spectrum of patients at risk of IFIs.
Roya Vahedi-Shahandashti +3 more
doaj +1 more source
Increasing Terbinafine Resistance in Danish Trichophyton Isolates 2019–2020 [PDF]
, 2022 Terbinafine resistance in Trichophyton species has emerged and appears to be increasing. A new EUCAST susceptibility testing method and tentative ECOFFs were recently proposed for Trichophyton.
Arendrup, Maiken Cavling +5 more
core +2 more sources
Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices
APMIS, Volume 131, Issue 11, Page 654-667, November 2023., 2023 The prevalence of invasive pulmonary aspergillosis (IPA) is growing in critically ill patients in the intensive care unit (ICU). It is increasingly recognized in immunocompetent hosts and immunocompromised ones. IPA frequently complicates both severe influenza and severe coronavirus disease 2019 (COVID‐19) infection.
Sarah Gaffney +4 more
wiley +1 more source
Internal Medicine Journal, Volume 53, Issue 8, Page 1489-1491, August 2023., 2023 Abstract Scedosporium and Lomentospora species are environmental moulds that are virulent in immunocompromised hosts and rarely cause bloodstream infection (BSI). Patients with Scedosporium and Lomentospora species BSI were identified by the state public laboratory service in Queensland, Australia, over a 20‐year period.
Adam G. Stewart +5 more
wiley +1 more source
Invasive aspergillosis in liver transplant recipients
Transplant Infectious Disease, Volume 25, Issue 3, June 2023., 2023 Abbreviations: Ciclos, cyclosporine; CNS, central nervous system; IA, invasive aspergillosis; ICU, intensive care unit; IS, immunosuppression; MELD, model for end‐stage liver disease; RBC, red blood cell; Tac, tacrolimus. aMultivariate analysis. *For invasive fungal infection. **For solid organ transplant.
Cléa Melenotte +11 more
wiley +1 more source
Antifungal chemotherapies and immunotherapies for the future
Parasite Immunology, Volume 45, Issue 2, February 2023., 2023 Abstract Human fungal pathogens cause a broad plethora of infections, spanning cutaneous dermatophytoses to invasive infections in immunocompromised hosts. As eukaryotic pathogens are capable of morphotype switching, they present unique challenges both for drug development and the immunological response.
Darius Armstrong‐James
wiley +1 more source
A Bibliometric Review on Candida auris of the First Fifteen Years of Research (2009‐2023)
BioMed Research International, Volume 2023, Issue 1, 2023., 2023 Introduction. Candida auris is a relatively novel pathogen first described in 2009 in Japan. It has increased its presence worldwide, becoming a public health concern due to its innate resistance to antifungals and outbreak potential. Methods.
Hiram Villanueva-Lozano +5 more
wiley +1 more source